

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

Per a February 12, 2009 Memorandum ("Memorandum"), during 2008-2009, Purdue agreed to purchase 4,000,000 shares of Common Stock of Infinity Pharmaceuticals, Inc. ("Infinity") at a purchase price of \$45 million. In addition, Purdue purchased 2,000,000 shares and warrants for 6,000,000 shares under the Second Closing at a purchase price of \$30 million.

On November 19, 2008, Purdue Pharmaceutical Products L.P. ("3XP")¹ and Purdue Pharma L.P. ("PPLP"), collectively "Purdue", entered into a Securities Purchase Agreement (the "Securities Agreement") with Infinity Pharmaceutical, Inc. ("Infinity"). Under the Securities Agreement, there are to be two separate closings. Under the Initial Closing, Infinity agrees to issue and sell and Purdue agrees to purchase 4 million shares of Common Stock, at a purchase price of \$45 million. Under the Second Closing, Infinity agrees to issue and sell and Purdue agrees to purchase 2 million shares of Common Stock, at a purchase price of \$30 million, and warrants to purchase up to 6 million shares of Common Stock.

¹3XP is a subsidiary of PPLP.

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

In 2008, per Purdue's audited financial statements, PPLP and 3XP purchased 4,000,000 shares of Infinity common stock at \$11.25 per share, which was higher than the market price of \$5.29 per share at the time. This excess amount paid by PPLP and 3XP for Infinity common stock "was recognized as [an] in-process research and development expense in 2008." Purdue transferred these 4,000,000 shares to PRA L.P. in 2008 for no consideration and recognized the transfer on its books and records at the market price of \$5.29 per share.

In connection with the strategic alliance agreements, PPLP and 3XP entered into a securities purchase agreement and line of credit agreement. Under the securities purchase agreement PPLP and 3XP purchased an aggregate of four million shares of Infinity common stock at a purchase price of \$11.25 per share for an aggregate purchase price of \$45 million. The excess of the aggregate amount paid by PPLP and 3XP for the Infinity common stock (\$11.25 per share) over the closing market price on the day before the first equity closing (\$5.29), approximately \$23.8 million, was recognized as in-process research and development expense in 2008.¹

Amount Paid by PPLP	In-Process R&D Expense	Transfer Amount
4,000,000 shares * 11.25 \$/Shr	4,000,000 shares * 5.96 \$/Shr	4,000,000 shares * 5.29 \$/Shr
\$ 45,000,000	\$ 23,840,000	\$ 21,160,000

¹E&Y audited financial statements YE 2009 and 2008.

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

In 2009, per Purdue's audited financial statements, PPLP and 3XP paid \$30 million to Infinity for 2,000,000 shares of Infinity common stock and warrants to purchase an additional 6,000,000 shares (at a strike price of \$15 per share), which was higher than the market price of \$7.27 per share at the time. This excess amount paid by PPLP and 3XP for Infinity common stock was again "recognized as [an] in-process research and development expense in 2009." Purdue transferred these 2,000,000 shares and warrants to PRA L.P. in 2009 for no consideration and recognized the transfer on its books and records at \$11.8 million.

(NOTE: On January 7, 2009 the shareholders of Infinity approved the issuance and sale of \$30 million of common stock and warrants to purchase up to six million additional shares of common stock at \$15 per unit, representing a significant premium over January 6, 2009 closing price of \$7.27 per share.¹

The excess of the aggregate amount paid by PPLP and 3XP for the second closing securities (\$30 million) over the fair market value of these securities (\$5.29 per share for the common stock and approximately \$1.3 million for the warrants) as of the day before the first equity closing, approximately \$18.2 million, was recognized as in-process research and development expense in 2009.²

Amount Paid by PPLP (A)	In-Process R&D Expense Shares (B)	In-Process R&D Expense Warrants (C)	Transfer Amount (D = A-B-C)
2,000,000 shares * 15.00 \$/Shr	2,000,000 shares * 7.73 \$/Shr	18,200,000 -	15,460,000
\$ 30,000,000	\$ 15,460,000	\$ 2,740,000	\$ 11,800,000

¹February 19, 2009 Memorandum of Infinity Pharmaceutical, Inc. Securities Purchase Agreement and Strategic Alliance Agreement

²EY Audited Financial Statement YE 2009-2008 at page 13

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

In November 2008, Purdue entered into an unsecured line of credit agreement with Infinity up to a maximum principal amount of \$50 million.

3. Collaboration Agreement with Infinity Pharmaceuticals, Inc.

In November 2008, PPLP's wholly owned subsidiary, Purdue Pharmaceutical Products L.P. ("3XP"), and an independent associated company entered into a global strategic alliance with Infinity Pharmaceuticals, Inc. ("Infinity"). In connection with the strategic alliance agreements, PPLP and 3XP entered into an unsecured line of credit agreement with Infinity up to an aggregate maximum principal amount of \$50 million, all of which was drawn down by Infinity during 2011. The extension of the line of credit was at an interest rate below Infinity's incremental borrowing rate and represented the transfer of additional value to Infinity in the arrangement. As such, the Companies recorded the fair value of the line of credit in the amount of \$17.3 million as a loan commitment liability on their balance sheet in 2008, which the Companies were amortizing to interest income over the life of the loan arrangement, or 10 years commencing on April 1, 2009.

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

In 2012, Infinity repaid all principal and interest amounts owed through (i) the issuance of 3,520,013 shares of common stock and (ii) an agreement to sell 1,896,552 shares of its common stock to PPLP at \$14.50 per share, which resulted in Purdue owning a total of 5,416,565 shares of Infinity common stock in 2012.

In 2012, PPLP renegotiated its agreement with Infinity. Under the terms of the renegotiated agreement, (a) 3XP would no longer provide research and development funding to Infinity, (b) PPLP agreed to purchase 1,896,552 shares of Infinity common stock for \$14.50 per share and (c) Infinity agreed to issue an additional 3,520,013 shares of common stock to PPLP to repay in full the principal and accrued interest outstanding under the \$50 million line of credit. As a result of the transaction, PPLP recorded other income of \$11.3 million to write off the deferred credit relating to the line of credit and \$13.4 million as a result of the difference in the fair value of the stock received as compared to the combined consideration paid by PPLP and the carrying value of the line of credit extinguished.¹

¹EY Audited Financial Statement YE 2013-2012

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

In 2013, Purdue transferred its 5,416,565 shares of Infinity common stock to PRA L.P. for no consideration and recognized this transfer on its books and records at the market price at the time of \$42.28 per share.

The Companies'

Notes to Combined Financial Statements (continued)

December 31, 2013

3. Collaboration Agreement with Infinity Pharmaceuticals, Inc. (continued)

In 2013, PPLP distributed the entire investment of 5,416,565 shares of Infinity common stock to its partners.¹ The fair value of the stock at the time of the distribution was \$42.48 per share. As a result of this distribution, PPLP realized a gain of \$138.0 million which is included in Other Operating Income, of which \$97.5 million represents the realization of the prior year unrealized gain recorded through other comprehensive income.

¹Per The October 19, 2018 MDL Presentation, partners identified as PRA L.P.

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

The \$21.2 million distribution in 2008 was recognized as follows in the 2008 audited financial statements.

The Companies' Combined Statement of Equity

	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Partners' Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	<i>(In thousands)</i>						
Balance at December 31, 2006	\$7	\$1,887	\$(999)	\$ 439,962	\$ 4,262	\$(1,799)	\$ 443,320
Net income	—	—	—	620,113	4,754	—	624,867
Other comprehensive income:							
Adoption of FAS 158, net of tax benefit of \$368	—	—	—	—	—	(4,748)	(4,748)
Total comprehensive income							620,119
Partners' capital distributions:							
Pharma Associates L.P.	—	—	—	(20)	—	—	(20)
Norwell Land Company	—	—	—	(765)	—	—	(765)
Purdue Pharma L.P.	—	—	—	(262,526)	—	—	(262,526)
Balance at December 31, 2007	\$7	\$1,887	\$(999)	\$796,764	\$9,016	\$(6,547)	\$800,128
Net income	—	—	—	1,350,429	1,561	—	1,351,990
Other comprehensive income:							
Employee benefit plans, net of tax benefit of \$2,002	—	—	—	—	—	(64,495)	(64,495)
Currency translation adjustment	—	—	—	—	—	1,598	1,598
Total comprehensive income							1,289,093
Investment contribution:							
Lucien Holdings S.a.r.l.	—	—	—	(41,216)	—	(139)	(41,355)
Investment distributions:							
Coventry Technologies LLC	—	—	—	(51,218)	(283)	(822)	(52,323)
Infinity Pharmaceuticals Inc.	—	—	—	(21,160)	—	—	(21,160)
Partners' capital distributions:							
Pharma Associates L.P.	—	—	—	(20)	—	—	(20)
Norwell Land Company	—	—	—	(801)	—	—	(801)
Purdue Pharma L.P.	—	—	—	(1,292,323)	—	—	(1,292,323)
Balance at December 31, 2008	\$7	\$1,887	\$(999)	\$740,455	\$10,294	\$(70,405)	\$681,239

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

The non-cash transfer was recognized as follows in PPLP's (SAP company code 208) accounting records. Below is the accounting of the \$21.2 million 2008 distribution.

208: Purdue Pharma L.P. ³ 401: PLP Assoc Holdings L.P. 413: BR Holdings Assoc. LP	Company	Account Number	Account Description	DR	CR
	208	302040	Dist IRC 1446	\$ 45,000,000	
	208	107950	Investment Infinity		\$ (22,500,000)
	208	102313	Purdue Pharm Prod LP		\$ (22,500,000)
	401	302032	Capital #32 Dist BR	\$ 45,000,000	
	401	107242	Invest-IRC 1446W/H		\$ (45,000,000)
	413	302026	Capital #26 Distribution	\$ 22,500,000	
	413	302027	Capital #27 Distribution	\$ 22,500,000	
	413	107401	Invest. PLP Asc.Hold		\$ (45,000,000)
	208	302040	Dist IRC 1446		\$ (21,613,389)
	208	800000	Misc. Charge/Expense	\$ 10,780,000	
	208	102313	Purdue Pharm Prod LP	\$ 10,780,000	
	401	302032	Capital #32 Dist BR		\$ (21,560,000)
	401	107242	Ivest-IRC 1446 W/H	\$ 21,560,000	
	413	302026	Capital #26 Distrib. 20090311		\$ (10,780,000)
	413	302027	Capital #27 Distrib. 20090311		\$ (10,780,000)
	413	107401	Invest. PLP Asc.Hold 20090311	\$ 21,560,000 ¹	
	208	302040	Dist IRC 1446		\$ (2,285,646)
	208	800000	Misc. Charge/Expense	\$ 1,140,000	
	208	102313	Purdue Pharm Prod LP	\$ 1,140,000	
	401	302032	Capital #32 Dist BR		\$ (2,280,000)
	401	107242	Invest-IRC 1446 W/H	\$ 2,280,000	
	413	302026	Capital #26 Distribution		\$ (1,140,000)
	413	302027	Capital #27 Distribution		\$ (1,140,000)
	413	107401	Invest. PLP Asc. Holding LP	\$ 2,280,000 ²	

¹Includes miscellaneous charge to 402 (PLP Associates Holdings Inc.) for \$53,389.44.

²Includes miscellaneous charge to 402 (PLP Associates Holdings Inc.) for \$5,646.01.

³PLP is a limited partner of PRA L.P. BR Holdings Associated L.P. is the parent of PLP

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2008 \$21.2 million transfer of equity through BR Holdings Associated. L.P. (an indirect parent of PPLP – SAP company code 413) and G/L accounts 302026 (equity) and 302027 (equity).

G/L Account		*											
Company Code		413											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 413	100000157	31.12.2008	23.01.2009	12	2008/12	SA		RC 1208 32	302026	GEN	Infinity Distribution reconciliation Dec 2008	22.500.000,00	USD
<input type="checkbox"/> 413	100000157	31.12.2008	23.01.2009	12	2008/12	SA		RC 1208 32	302027	GEN	Infinity Distribution reconciliation Dec 2008	22.500.000,00	USD
<input type="checkbox"/> 413	100000164	31.12.2008	11.03.2009	12	2008/12	SA		RC 1208 52	302026	GEN	Infinity premium reconciliation Dec 2008	10.780.000,00-	USD
<input type="checkbox"/> 413	100000164	31.12.2008	11.03.2009	12	2008/12	SA		RC 1208 52	302027	GEN	Infinity premium reconciliation Dec 2008	10.780.000,00-	USD
<input type="checkbox"/> 413	100000165	31.12.2008	25.03.2009	12	2008/12	SA		RC 1208 54	302026	GEN	Infinity premium reconciliation Dec 2008	1.140.000,00-	USD
<input type="checkbox"/> 413	100000165	31.12.2008	25.03.2009	12	2008/12	SA		RC 1208 54	302027	GEN	Infinity premium reconciliation Dec 2008	1.140.000,00-	USD
*												21.160.000,00	USD

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2008 \$21.2 million transfer of equity through BR Holdings Assoc. LP (an indirect parent of PPLP – SAP company code 413). Shown below is the initial \$45 million purchase.

G/L account document						
Overall No.		0100048066208 08		Doc. Currency USD		
CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference
Itm	PK Account	Account short text		Assignment	Tx	Amount Text
208	100048066	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
1	50 107950	Investment Infinity		20090123		22.500.000,00- Infinity Distribution reconciliation Dec 2008
2	40 302040	Dist IRC 1446		20090123		45.000.000,00 Infinity Distribution reconciliation Dec 2008
3	40 302042	Dist #42 PP Inc		20090123		111.927,82 Infinity Distribution reconciliation Dec 2008
4	50 102301	Purdue Pharma Inc.		20090123		111.927,82-
5	50 102313	Purdue Pharm Prod LP		20090123		22.500.000,00-
6	50 102402	PLP Assoc Holdings		20090123		111.434,36-
7	40 102412	IRC 1446 W/H Partner		20090123		111.434,36
301	100000289	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
310	100000049	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
313	100008605	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
401	100000373	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
1	40 302032	Capital #32 Dist BR		20090123		45.000.000,00 Infinity Distribution reconciliation Dec 2008
2	50 107242	Invest-IRC 1446 W/H		20090123		45.000.000,00- Infinity Distribution reconciliation Dec 2008
402	100000180	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
1	50 107412	Invest. IRC 1446 W/H		20090123		111.434,36- Infinity Distribution reconciliation Dec 2008
2	40 102208	Purdue Pharma L.P.		20090123		111.434,36
410	100000084	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
412	100000176	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
413	100000157	2008	SA	23.01.2009	31.12.2008	RC 1208 32 USD
1	40 302026	Capital #26 Distrib.		20090123		22.500.000,00 Infinity Distribution reconciliation Dec 2008
2	40 302027	Capital #27 Distrib.		20090123		22.500.000,00 Infinity Distribution reconciliation Dec 2008
3	50 107401	Invest. PLP Asc.Hold		20090123		45.000.000,00- Infinity Distribution reconciliation Dec 2008

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2008 \$21.2 million transfer of equity through BR Holdings Assoc. LP (an indirect parent of PPLP – SAP company code 413). Shown below is the first of two adjustments for in process R&D expense as explained in previous slides.

G/L account document

Overall No. 0100050236208 08 Doc. Currency USD

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK Account	Account short text		Assignment		Tx	Amount Text
1	50 302042	Dist #42 PP Inc		20090311			53.625,86- Infinity premium reconciliation Dec 2008
2	50 302040	Dist IRC 1446		20090311			21.613.389,44- Infinity premium reconciliation Dec 2008
3	40 800000	Misc. Charge/Expense		20090311			10.780.000,00 Infinity premium reconciliation Dec 2008
4	40 102301	Purdue Pharma Inc.		20090311			53.625,86
5	40 102313	Purdue Pharm Prod LP		20090311			10.780.000,00
6	40 102402	PLP Assoc Holdings		20090311			53.389,44
301	100000311	2008	SA	11.03.2009	31.12.2008	RC 1208 52	USD
310	100000054	2008	SA	11.03.2009	31.12.2008	RC 1208 52	USD
313	100008927	2008	SA	11.03.2009	31.12.2008	RC 1208 52	USD
401	100000393	2008	SA	11.03.2009	31.12.2008	RC 1208 52	USD
1	50 302032	Capital #32 Dist BR		20090311			21.560.000,00- Infinity premium reconciliation Dec 2008
2	40 107242	Invest-IRC 1446 W/H		20090311			21.560.000,00 Infinity premium reconciliation Dec 2008
402	100000190	2008	SA	11.03.2009	31.12.2008	RC 1208 52	USD
1	40 107412	Invest. IRC 1446 W/H		20090311			53.389,44 Infinity premium reconciliation Dec 2008
2	50 102208	Purdue Pharma L.P.		20090311			53.389,44-
410	100000090	2008	SA	11.03.2009	31.12.2008	RC 1208 52	USD
412	100000190	2008	SA	11.03.2009	31.12.2008	RC 1208 52	USD
413	100000164	2008	SA	11.03.2009	31.12.2008	RC 1208 52	USD
1	50 302026	Capital #26 Distrib.		20090311			10.780.000,00- Infinity premium reconciliation Dec 2008
2	50 302027	Capital #27 Distrib.		20090311			10.780.000,00- Infinity premium reconciliation Dec 2008
3	40 107401	Invest. PLP Asc.Hold		20090311			21.560.000,00 Infinity premium reconciliation Dec 2008

¹Includes miscellaneous charge to 402 (PLP Associates Holdings Inc.) for \$53,389.44

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2008 \$21.2 million transfer of equity through BR Holdings Assoc. LP (an indirect parent of PPLP – SAP company code 413). Shown below is the second adjustment for in process R&D expense as explained in previous slides.

G/L account document

Overall No. 0100050583208 08 Doc. Currency USD

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK Account	Account short text			Assignment	Tx	Amount Text
208	100050583	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
1 50	302042	Dist #42 PP Inc			20090325		5.671,01- Infinity premium reconciliation Dec 2008
2 50	302040	Dist IRC 1446			20090325		2.285.646,01- Infinity premium reconciliation Dec 2008
3 40	800000	Misc. Charge/Expense			20090325		1.140.000,00 Infinity premium reconciliation Dec 2008
4 40	102301	Purdue Pharma Inc.			20090325		5.671,01
5 40	102313	Purdue Pharm Prod LP			20090325		1.140.000,00
6 40	102402	PLP Assoc Holdings			20090325		5.646,01
301	100000314	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
310	100000055	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
313	100008931	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
401	100000395	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
1 50	302032	Capital #32 Dist BR			20090325		2.280.000,00- Infinity premium reconciliation Dec 2008
2 40	107242	Invest-IRC 1446 W/H			20090325		2.280.000,00 Infinity premium reconciliation Dec 2008
402	100000193	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
1 40	107412	Invest. IRC 1446 W/H			20090325		5.646,01 Infinity premium reconciliation Dec 2008
2 50	102208	Purdue Pharma L.P.			20090325		5.646,01-
410	100000091	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
412	100000193	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
413	100000165	2008	SA	25.03.2009	31.12.2008	RC 1208 54	USD
1 50	302026	Capital #26 Distrib.			20090325		1.140.000,00- Infinity premium reconciliation Dec 2008
2 50	302027	Capital #27 Distrib.			20090325		1.140.000,00- Infinity premium reconciliation Dec 2008
3 40	107401	Invest. PLP Asc.Hold			20090325		2.280.000,00 Infinity premium reconciliation Dec 2008

¹Includes miscellaneous charge to 402 (PLP Associates Holdings Inc.) for \$5,646.01

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

The \$11.8 million distribution in 2009 was recognized as follows in PPLP's 2009 audited financial statements.

The Companies' Combined Statement of Equity

	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Partners' Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	<i>(In thousands)</i>						
Balance at December 31, 2007	\$7	\$1,887	\$(999)	\$ 796,764	\$ 9,016	\$(6,547)	\$ 800,128
Net income	-	-	-	1,350,429	1,561	-	1,351,990
Other comprehensive income:							
Employee benefit plans, net of tax benefit of \$2,002	-	-	-	-	-	(64,495)	(64,495)
Currency translation adjustment	-	-	-	-	-	1,598	1,598
Total comprehensive income							1,289,093
Investment contribution:							
Lucien Holdings S.ar.l.	-	-	-	(41,216)	-	(139)	(41,355)
Investment distributions:							
Coventry Technologies L.P.	-	-	-	(51,218)	(283)	(822)	(52,323)
Infinity Pharmaceuticals Inc.	-	-	-	(21,160)	-	-	(21,160)
Partners' capital distributions:							
Pharma Associates L.P.	-	-	-	(20)	-	-	(20)
Norvell Land Company	-	-	-	(801)	-	-	(801)
Purdue Pharma L.P.	-	-	-	(1,292,323)	-	-	(1,292,323)
Balance at December 31, 2008	\$7	\$1,887	\$(999)	\$740,455	\$10,294	\$(70,405)	\$ 681,239
Deconsolidation of Purdue Pharma Inc.	(1)	(499)	-	-	(573)	-	(1,073)
Deconsolidation of Millsaw Realty Inc.	(1)	-	-	-	(14)	-	(15)
Net income	-	-	-	1,576,714	4,756	-	1,581,470
Other comprehensive income:							
Employee benefit plans, net of tax of \$227	-	-	-	-	-	(9,525)	(9,525)
Currency translation adjustment	-	-	-	-	-	3,005	3,005
Total comprehensive income							1,574,950
Investment distributions:							
Millsaw Realty L.P.	-	-	-	(7,412)	-	-	(7,412)
Infinity Pharmaceuticals Inc.	-	-	-	(11,830)	-	-	(11,830)
Other	-	-	-	(36,090)	-	-	(36,090)
Partners' capital contributions:							
Purdue Pharma L.P.	-	-	-	1,186	-	-	1,186
Partners' capital distributions:							
Pharma Associates L.P.	-	-	-	(20)	-	-	(20)
Norvell Land Company	-	-	-	(742)	-	-	(742)
Purdue Pharma L.P.	-	-	-	(1,609,865)	-	-	(1,609,865)
Balance at December 31, 2009	\$5	\$1,388	\$(999)	\$652,396	\$14,463	\$(76,925)	\$ 590,328

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

The non-cash transfer was recognized as follows in PPLP's (SAP company code 208) accounting records. Below is the accounting of the \$11.8 million 2009 distribution.

	Company	Account Number	Account Description	DR	CR
208: Purdue Pharma L.P.	208	302044	Dist #44 PLPAH LP	\$ 30,000,000	
401: PLP Assoc Holdings L.P.	208	107950	Investment Infinity		\$ (15,000,000)
413: BR Holdings Assoc. LP	208	102313	Purdue Pharm Prod LP		(15,000,000)
	401	302032	Capital #32 Dist BR	39,012,199 ¹	
	401	107204	Invest - PPLP		(39,012,199)
	413	107401	Invest. PLP Asc.Hold		(39,012,199)
	413	302026	Capital #26 Distribution	19,506,099	
	413	302027	Capital #27 Distribution	19,506,099	
<hr/>					
	208	302044	Dist #44 PLPAH LP	\$ 18,170,000	
	208	800000	Misc. Charge/Expense		\$ (18,170,000)
	401	302032	Capital #32 Dist BR	18,170,000	
	401	107204	Invest - PPLP		(18,170,000)
	413	302026	Capital #26 Distrib. 20100328	9,085,000	
	413	302027	Capital #27 Distrib. 20100328	9,085,000	
	413	107401	Invest. PLP Asc.Hold 20100328		(18,170,000)

¹This transfer includes a \$10 million distribution of Novelos stock from Purdue to PRA L.P. in 2009, which was partially offset by miscellaneous NJ Refunds/Interest in the amount of \$987,802.22 (\$10,000,000 - \$987,801.22 = \$9,012,198.78).

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2009 \$11.8 million transfer of equity through PPLP's (SAP company code 208) G/L account 302044 (equity).

G/L Account		302044		Distribution #44 PLP Assoc. Holdings LP									
Company Code		208											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 208	100050035	28.02.2009	04.03.2009	2	2009/02	SA		RC 0209 03	302044	GEN	Infinity Distribution	30.000.000,00	USD
<input type="checkbox"/> 208	100052251	31.05.2009	02.06.2009	5	2009/05	SA		KEC 0509 3	302044	GEN	Infinity Adj	18.170.000,00-	USD
*												11.830.000,00	USD

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2009 \$11.8 million transfer of equity through BR Holdings Assoc. LP (an indirect parent of PPLP – SAP company code 413). Shown below is the original \$30 million purchase.

G/L account document						
Overall No.	0100050035208 09	Doc. Currency USD				

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy	
Itm	PK Account	Account short text		Assignment	Tx	Amount	Text	
208	100050035	2009	SA	04.03.2009	28.02.2009	RC 0209 03	USD	
1 40	302044	Dist #44 PLPAH LP	20090304			30.000.000,00	Infinity Distribution	
2 50	107950	Investment Infinity	20090304			15.000.000,00	Infinity Distribution	
3 40	302043	Dist #43 PLPAH Inc	20090304			74.289,57	Infinity Distribution	
4 40	302042	Dist #42 PP Inc	20090304			74.618,55	Infinity Distribution	
5 40	302044	Dist #44 PLPAH LP	20090304			10.000.000,00	Novelos Distribution	
6 50	107955	Investment Novelos	20090304			10.000.000,00	Novelos Distribution	
7 40	302043	Dist #43 PLPAH Inc	20090304			24.763,19	Novelos Distribution	
8 40	302042	Dist #42 PP Inc	20090304			24.872,85	Novelos Distribution	
9 40	302040	Dist IRC 1446	20090304			961.731,70	NJ Refund	
10 50	302044	Dist #44 PLPAH LP	20090304			961.731,70	NJ Refund	
11 50	302043	Dist #43 PLPAH Inc	20090304			2.381,55	NJ Refund	
12 50	302042	Dist #42 PP Inc	20090304			2.392,10	NJ Refund	
13 40	302040	Dist IRC 1446	20090304			25.268,30	NJ Refund - Interest	
14 50	302044	Dist #44 PLPAH LP	20090304			25.268,30	NJ Refund - Interest	
15 50	302043	Dist #43 PLPAH Inc	20090304			62,57	NJ Refund - Interest	
16 50	302042	Dist #42 PP Inc	20090304			62,85	NJ Refund - Interest	
17 50	302044	Dist #44 PLPAH LP	20090304			801,22	NC Refund	
18 50	302043	Dist #43 PLPAH Inc	20090304			1,98	NC Refund	
19 50	302042	Dist #42 PP Inc	20090304			1,99	NC Refund	
20 50	102301	Purdue Pharma Inc.	20090304			97.034,46		
21 50	102313	Purdue Pharm Prod LP	20090304			15.000.000,00		
22 50	102402	PLP Assoc Holdings	20090304			96.606,66		
23 40	102412	IRC 1446 W/H Partner	20090304			801,22		
401	100000388	2009	SA	04.03.2009	28.02.2009	RC 0209 03	USD	
1 50	107204	Invest - PPLP	20090304			39.012.198,78	February Distributions	
2 40	302032	Capital #32 Dist BR	20090304			39.012.198,78	February Distributions	
413	100000162	2009	SA	04.03.2009	28.02.2009	RC 0209 03	USD	
1 40	302026	Capital #26 Distrib.	20090304			19.506.099,39	February Distributions	
2 40	302027	Capital #27 Distrib.	20090304			19.506.099,39	February Distributions	
3 50	107401	Invest. PLP Asc.Hold	20090304			39.012.198,78	February Distributions	

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2009 \$11.8 million transfer of equity through BR Holdings Associated L.P. (an indirect parent of PPLP – SAP company code 413). Shown below is the adjustment for in-process R&D expense as explained in previous slides.

G/L account document

Overall No.0100065869208 09Doc. Currency USD

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK Account	Account short text			Assignment	Tx	Amount Text
2	50 800000	Misc. Charge/Expense			20100328		18.170.000,00- To adjust 2009 equity distributions
3	40 302043	Dist #43 PLPAH Inc			20100328		44.994,72 To adjust 2009 equity distributions
4	50 102402	PLP Assoc Holdings			20100328		44.994,72- To adjust 2009 equity distributions
5	40 302042	Dist #42 PP Inc			20100328		45.193,97 To adjust 2009 equity distributions
6	50 102301	Purdue Pharma Inc.			20100328		45.193,97- To adjust 2009 equity distributions
301	100000480	2009	SA	28.03.2010	31.12.2009	KEC 1209 28	USD
401	100000578	2009	SA	28.03.2010	31.12.2009	KEC 1209 28	USD
1	50 107204	Invest - PPLP			20100328		18.170.000,00- To adjust 2009 equity distributions
2	40 302032	Capital #32 Dist BR			20100328		18.170.000,00 To adjust 2009 equity distributions
402	100000315	2009	SA	28.03.2010	31.12.2009	KEC 1209 28	USD
410	100000163	2009	SA	28.03.2010	31.12.2009	KEC 1209 28	USD
413	100000251	2009	SA	28.03.2010	31.12.2009	KEC 1209 28	USD
1	40 302026	Capital #26 Distrib.			20100328		9.085.000,00 To adjust 2009 equity distributions
2	40 302027	Capital #27 Distrib.			20100328		9.085.000,00 To adjust 2009 equity distributions
3	50 107401	Invest. PLP Asc.Hold			20100328		18.170.000,00- To adjust 2009 equity distributions

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

The 2013 transfer of stock was valued as the sum of the 2012 shares acquired times the publicly available share price ($5,416,565 * \$42.48/\text{Shr} = \$230,095,681$). Per the audited financial statements:

The Companies'

Notes to Combined Financial Statements (continued)

December 31, 2013

3. Collaboration Agreement with Infinity Pharmaceuticals, Inc. (continued)

In 2013, PPLP distributed the entire investment of 5,416,565 shares of Infinity common stock to its partners.¹ The fair value of the stock at the time of the distribution was \$42.48 per share. As a result of this distribution, PPLP realized a gain of \$138.0 million which is included in Other Operating Income, of which \$97.5 million represents the realization of the prior year unrealized gain recorded through other comprehensive income.

¹Per the October 19, 2018 MDL Presentation, partners are identified as PRA L.P.

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

The non-cash transfer was recognized as follows in PPLP's (SAP company code 208) accounting records. Below is the accounting of the \$230 million 2013 distribution.

	Company	Account Number	Account Description	DR	CR
208: Purdue Pharma L.P. 401: PLP Assoc Holdings L.P. 413: BR Holdings Assoc. LP 416: Pharmaceutical Research Associates L.P.	208	103070	Marketable Security		\$ (230,095,681)
	208	302045	Dist #45 PH LP	\$ 230,095,681	
	208	102416	Purdue Holdings LP		\$ (230,095,681)
	208	102413	BR Holdings Assoc LP	\$ 216,662,600	
	208	102416	Purdue Holdings LP	\$ 13,433,081	
	401	107416	Invest - PH LP		\$ (216,662,600)
	401	102416	Purdue Holdings LP	\$ 216,662,600	
	401	302032	Capital #32 Dist BR	\$ 216,662,600	
	401	102413	BR Holdings Assoc LP		\$ (216,662,600)
	413	102401	PLP Assoc Holdings	\$ 216,662,600	
	413	102208	Purdue Pharma L.P.		\$ (216,662,600)
	413	302026	Capital #26 Distribution	\$ 108,331,300	
	413	302027	Capital #27 Distribution	\$ 108,331,300	
	413	102208	Purdue Pharma L.P.		\$ (216,662,600)
	416	103070	Marketable Security	\$ 13,433,081	
	416	102208	Purdue Pharma L.P.		\$ (13,433,081)
	416	302044	Dist #44 PLPAH LP	\$ 216,662,600	
	416	102401	PLP Assoc Holdings		\$ (216,662,600)
	416	102208	Purdue Pharma L.P.	\$ 230,095,681	
	416	107204	Invest - PPLP		\$ (230,095,681)

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

The non-cash transfer was recognized as follows in PPLP's (SAP company code 208) accounting records. Below is the accounting of the \$230 million 2013 distribution.

	Company	Account Number	Account Description	DR	CR
	208	103070	Marketable Security		\$(230,095,681)
208: Purdue Pharma L.P.	208	302045	Dist #45 PH LP	\$230,095,681	
401: PLP Assoc Holdings L.P.	208	102416	Purdue Holdings LP		\$(230,095,681)
413: BR Holdings Assoc. LP	208	102413	BR Holdings Assoc LP	\$216,662,600	
416: Pharmaceutical Research Associates L.P.	208	102416	Purdue Holdings LP	\$ 13,433,081	
	401	17416	Invest - PH LP		\$(216,662,600)
	401	102416	Purdue Holdings LP	\$216,662,600	
	401	302032	Capital #32 Dist BR	\$216,662,600	
	401	102413	BR Holdings Assoc LP		\$(216,662,600)
	413	102401	PLP Assoc Holdings	\$216,662,600	
	413	107401	Invest. PLP Asc. Hold		\$(216,662,600)
	413	302026	Capital #26 Distribution	\$108,331,300	
	413	302027	Capital #27 Distribution	\$108,331,300	
	413	102208	Purdue Pharma L.P.		\$(216,662,600)
	416	103070	Marketable Security	\$ 13,433,081	
	416	102208	Purdue Pharma L.P.		\$ (13,433,081)
	416	302044	Dist #44 PLPAH LP	\$216,662,600	
	416	102401	PLP Assoc Holdings		\$(216,662,600)
	416	102208	Purdue Pharma L.P.	\$230,095,681	
	416	107204	Invest - PPLP		\$(230,095,681)

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2013 \$230.1 million transfer of equity through PPLP's (SAP company code 208) G/L accounts 302045 (equity) and 103070 (other receivables).

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100124958	Company Code	208	Fiscal Year	2013
Doc. Date	12.08.2013	Posting Date	30.04.2013	Period	04
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	RC 0413 37	Overall No.	0100124958208 13		
Doc. Currency	USD				
Doc. Hdr Text	Infinity				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	103070	Marketable Security		GEN			32.445.224,35-	Fair Value Adjustment 04.2013
2	40	330007	Unreal Gain/Loss Inv		GEN			32.445.224,35	Fair Value Adjustment 04.2013
3	50	700090	Gain On Investments	9000208	GEN			138.014.076,20-	Realize Gain
4	40	330007	Unreal Gain/Loss Inv		GEN			138.014.076,20	Realize Gain
5	50	103070	Marketable Security		GEN			230.095.681,20-	Infinity Distribution
6	40	302045	Dist #45 PH LP		GEN			230.095.681,20	Infinity Distribution
7	50	102416	Purdue Holdings LP		GEN			230.095.681,20-	Infinity Distribution
8	40	102413	BR Holdings Assoc LP		GEN			216.662.600,00	
9	40	102416	Purdue Holdings LP		GEN			13.433.081,20	

Exhibit 4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013 at a valuation of \$263.1 million

SAP contains support for the 2013 \$230.1 million transfer of equity to PRA L.P. (SAP company code 416).

G/L account document									
Overall No.		0100124958208 13		Doc. Currency		USD			

Exhibit 4C: Transfer from Purdue of its equity interest in Millsaw Realty L.P. to PRA L.P. in 2009 at a valuation of \$7.4 million

On January 1, 2009, PPLP and PLPAH entered into an assignment and assumption agreement.

ASSIGNMENT AND ASSUMPTION AGREEMENT

This Assignment and Assumption Agreement (the "Agreement") effective January 1, 2009 (the "Assignment Date") by and between Purdue Pharma L.P., a Delaware limited partnership ("Assignor"), and PLP Associates Holdings L.P., a Delaware limited partnership ("Assignee");

W I T N E S S E T H :

WHEREAS, Assignor desires to assign to Assignee, and Assignee desires to assume, 100% of the limited partnership interest in Millsaw Realty L.P., a Delaware limited partnership, held by Assignor (the "Partnership Interest"), all upon the terms and conditions set forth herein;

NOW, THEREFORE, in consideration of the promises and mutual covenants set forth herein, the parties hereto agree as follows:

1. Assignment. Assignor does hereby convey, transfer, assign and deliver to Assignee, and Assignee does hereby accept from Assignor, all of Assignor's right, title and interest in and to all of the Partnership Interest, to have and to hold the Partnership Interest hereby conveyed, transferred, assigned and delivered unto Assignee, its successors and assigns, to its and their own use and behalf forever.

Exhibit 4C: Transfer from Purdue of its equity interest in Millsaw Realty L.P. to PRA L.P. in 2009 at a valuation of \$7.4 million

On January 1, 2009, PPI consented to the transfer of 100% interest in Millsaw Realty L.P. to PLPAH.

PURDUE PHARMA L.P.

Written Consent of General Partner

The undersigned, Purdue Pharma Inc. ("PPI"), being the General Partner of Purdue Pharma L.P., a Delaware general partnership (the "Partnership"), in accordance with the Purdue Pharma L.P. Amended and Restated Limited Partnership Agreement dated as of January 2, 1997, hereby consents to the taking of the following actions and directs that this consent be filed with the minutes of proceedings of the Partnership:

RESOLVED, that the Partnership be and it hereby is authorized and directed to distribute to PLP Associates Holdings L.P, a Delaware limited partnership ("PLP"), 100 percent of the Partnership's limited partnership interest in Millsaw Realty L.P. ("Millsaw"), a Delaware limited partnership (the "Millsaw Distribution"); and further

RESOLVED, that, in connection with the Millsaw Distribution, the Assignment and Assumption Agreement by and between the Partnership and PLP (the "Assignment Agreement") in the form presented to PPI be and it hereby is approved; and further

Exhibit 4C: Transfer from Purdue of its equity interest in Millsaw Realty L.P. to PRA L.P. in 2009 at a valuation of \$7.4 million

Per the 2009 audited financial statements, Purdue transferred the equity interest at its book value of \$7.4 million.

The Companies' Combined Statement of Equity

	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Partners' Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	<i>(In thousands)</i>						
Balance at December 31, 2007	\$7	\$1,887	\$(999)	\$ 796,764	\$ 9,016	\$(6,547)	\$ 800,128
Net income	—	—	—	1,350,429	1,561	—	1,351,990
Other comprehensive income:							
Employee benefit plans, net of tax benefit of \$2,002	—	—	—	—	—	(64,495)	(64,495)
Currency translation adjustment	—	—	—	—	—	1,598	1,598
Total comprehensive income							1,289,093
Investment contribution:							
Lucien Holdings S.ar.l.	—	—	—	(41,216)	—	(139)	(41,355)
Investment distributions:							
Coventry Technologies L.P.	—	—	—	(51,218)	(283)	(822)	(52,323)
Infinity Pharmaceuticals Inc.	—	—	—	(21,160)	—	—	(21,160)
Partners' capital distributions:							
Pharma Associates L.P.	—	—	—	(20)	—	—	(20)
Norwell Land Company	—	—	—	(801)	—	—	(801)
Purdue Pharma L.P.	—	—	—	(1,292,323)	—	—	(1,292,323)
Balance at December 31, 2008	\$7	\$1,887	\$(999)	\$740,455	\$10,294	\$(70,405)	\$ 681,239
Deconsolidation of Purdue Pharma Inc.	(1)	(499)	—	—	(573)	—	(1,073)
Deconsolidation of Millsaw Realty Inc.	(1)	—	—	—	(14)	—	(15)
Net income	—	—	—	1,576,714	4,756	—	1,581,470
Other comprehensive income:							
Employee benefit plans, net of tax of \$227	—	—	—	—	—	(9,525)	(9,525)
Currency translation adjustment	—	—	—	—	—	3,005	3,005
Total comprehensive income							1,574,950
Investment distributions:							
Millsaw Realty L.P.	—	—	—	(7,412)	—	—	(7,412)
Infinity Pharmaceuticals Inc.	—	—	—	(11,830)	—	—	(11,830)
Other	—	—	—	(36,090)	—	—	(36,090)
Partners' capital contributions:							
Purdue Pharma L.P.	—	—	—	1,186	—	—	1,186
Partners' capital distributions:							
Pharma Associates L.P.	—	—	—	(20)	—	—	(20)
Norwell Land Company	—	—	—	(742)	—	—	(742)
Purdue Pharma L.P.	—	—	—	(1,609,865)	—	—	(1,609,865)
Balance at December 31, 2009	\$5	\$1,388	\$(999)	\$652,396	\$14,463	\$(76,925)	\$ 590,328

3. Changes in Ownership

On January 1, 2009, PPLP distributed its ownership interest in Millsaw Realty L.P. ("Millsaw") to PPLP's limited partner. Concurrent with the distribution of Millsaw Realty L.P., its general partner, Millsaw Realty Inc., was released from its obligations under the 2006 Revolving Credit Facility (see Note 16) and was removed from the Companies' combined financial statements.

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

On May 1, 2008, Purdue agreed to purchase up to an initial \$10 million investment of Series A Convertible Preferred Stock of Kolltan.

SUMMARY TERM SHEET **Series A Convertible Preferred Stock**

The following is a summary of the principal terms of Series A Convertible Preferred Stock offered by Kolltan Pharmaceuticals, Inc., a Delaware corporation, to investors.

Issuer:	Kolltan Pharmaceuticals, Inc., a Delaware corporation (the “Company”)
Total Amount:	Up to \$10.0 million, subject to increase based on demand. There is no minimum amount of the offering required for the completion of the closing.
Securities:	Series A Convertible Preferred Stock (the “Series A Preferred Stock”) issued in a private placement exempt from registration under the Securities Act of 1933, as amended.
Price:	\$1.00 per share (the “Purchase Price”), representing a “pre-money” valuation of \$20 million.
Use of Proceeds:	General working capital purposes.
Dividends:	The Series A Preferred Stock will be entitled to receive dividends on an “as if” converted basis if the Company declares or pays any dividend on its Common Stock.

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

On August 7, 2008, the Board of Directors of Purdue authorized an increase in investment amount of \$1.5 million that resulted in a total investment of \$11.5 million.

DECISION

August 7, 2008

Increase -- Proposed Investment in Kolltan Pharmaceuticals, Inc.

It was decided to increase by \$1.5 million Purdue Pharma L.P.'s ("PPLP") investment in Kolltan Pharmaceuticals, Inc. ("Kolltan"), a startup company in the business of discovering and developing drugs for the oncology market, thereby authorizing PPLP to invest a total of \$11.5 million in Kolltan pursuant to the terms set forth in the previous Decision of June 24, 2008 authorizing the investment in Kolltan.

(Decision of the Board of Directors of Purdue Pharma Inc., as the general partner of Purdue Pharma L.P.)

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

On December 22, 2008, an additional investment in the amount of \$1.45 million was authorized, which resulted in a total investment of \$12.95 million in Kolltan.

Please prepare the wire transfer.

■



-----Original Message-----

From: ■

Sent: Monday, December 22, 2008 10:53 AM

To: ■

Cc: ■

Subject: FW: Kolltan Series A - Document Packet (27.86)

Importance: High

■ and ■

Dr. Richard has approved an additional investment in Kolltan. This is an "add on" to the Series A. The additional investment is \$1.45 million, which is our pro-rata share of the additional raise.

I have enclosed the email approval for the transaction.

■ can you please advise us on this?

■ can you please prepare a wire transfer for \$1.45 million after ■ gives us the approval?

■

I will be in the office today and tomorrow.

From: ■

Sent: Friday, November 21, 2008 2:25 PM

To: Sackler, Dr Richard

Subject: FW: Kolltan - 2 things for you to review and approve

Richard -

Please review and approve these 2 things:

1. Extended financing. You agreed that you would want to take a "pro-rata" share of the next \$4.5 million additional money they are raising. Your calculation is now: \$1.45 million (\$11.5/\$35.5 = 32%; 32% of \$4.5 = \$1.45). Do you approve \$1.45?

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

On March 4, 2014, the Board of Directors of PPI approved the purchase of 2,050,000 Series D Shares at \$1 per share for an additional investment of \$2.05 million, as well as a cash payment of \$10,175 to PRA L.P.

PURDUE PHARMA L.P.

Written Consent of General Partner

The undersigned, Purdue Pharma Inc. (the "General Partner"), a New York corporation and the General Partner of Purdue Pharma L.P., a Delaware limited partnership (the "Partnership"), hereby consents to the taking of the following actions and directs that this consent be filed with the minutes of proceedings of the Partnership:

RESOLVED, that the Partnership be and it hereby is authorized and directed to purchase 2,050,000 Series D Shares (the "Shares") of Kolltan Pharmaceuticals, Inc., a Delaware corporation, at a purchase price of \$2,050,000 (i.e. \$1.00 per Share) as part of Kolltan's Series D round financing; and further

RESOLVED, that once the Shares are owned by the Partnership, the Partnership be and it hereby is authorized and directed to distribute all of the Shares and make a payment in the amount of \$10,175 to Purdue Holdings L.P, a Delaware limited partnership; and further

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

By March 13, 2014, Purdue had invested \$12.95 million in Series A Preferred Stock and \$2.05 million in Series D Preferred Stock. Additionally, Purdue exercised 132,616 Common Shares in 2014 (valued at \$110,080).

From: [REDACTED]
Sent: Sunday, October 23, 2016 11:48 AM
To: [REDACTED]; [REDACTED]
Cc: [REDACTED]; [REDACTED]
Subject: RE: support agreement

All,

Below are the details of the equity investment in Kolltan:

Equity investment in multiple rounds by Purdue that was transferred 50/50 to Beacon and Rosebay

- Series A Preferred Shares investment of \$12.95 million in multiple tranches from July 24, 2008 - August 6, 2009
- Series D Preferred Shares investment of \$2.05 million on March 13, 2014
- Common Shares acquired by Purdue Board Member, for serving on Kolltan's Board of Directors and Scientific Advisory Board.
 - Received option grants that had to be exercised in 2014 since they had resigned their positions in contemplation that Kolltan was planning an IPO (the IPO has not yet occurred)

66,313 Common Shares owned by Beacon

66,313 Common Shares owned by Rosebay

- As of December 31, 2015, Beacon and Rosebay each own 4.26% of the equity of Kolltan on a fully diluted basis

[REDACTED]

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

A September 2009 distributions calculation details the transfer of the \$12.95 million Series A investment to Reigo and Rosebay at book value.¹

PPLP September Distributions

	<u>Kolltan</u>
PPLP Distribution	13,014,278.67
Purdue Pharma Inc. (0.2475%)	32,210.34
PLP Associates Holdings Inc. $[(244.55/99000)*(100\%-0.2475\%)]$	32,068.33
PLP Associates Holdings L.P. $[(98755.45/99000)*(100\%-0.2475\%)]$	<u>12,950,000.00</u>
Sub for gross up calculation only	12,982,068.33
To BR Holdings and then the Partners	12,950,000.00
Reigo (50%)	<u>6,475,000.00</u>
Rosebay (50%)	<u>6,475,000.00</u>

¹Reigo and Rosebay are the ultimate parent entities of PPLP (i.e., each hold a 50% ownership interest).

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

Additionally, the September 2009 distributions file details how the Kolltan transfer was executed in SAP.

	<u>Dr</u>	<u>Cr</u>
Step 1: Reclass from accounts where originally posted		
208 - 302044	12,950,000.00	
208 - 130160		12,950,000.00
 Step 2: Gross up the PPLP Distribution		
401 - 302043 Dist #43 PLPAH Inc	32,068.33	
402 - 107204 Invest - PPLP		32,068.33
410 - 302043 Dist #43 PLPAH Inc		32,068.33
410 - 107204 Invest - PPLP	32,068.33	
208 - 302042 PP INC	32,210.34	
301 - 107204 Invest - PPLP		32,210.34
310 - 302042 Dist #42 PP Inc		32,210.34
310 - 107204 Invest - PPLP	32,210.34	
 Step 3: Record the flow from BR Holdings to the Partners		
401 - 107204 Invest - PPLP		12,950,000.00
401 - 302032 Capital #32 Dist BR	12,950,000.00	
413 - 302026 Capital #26 Distrib.	6,475,000.00	
413 - 302027 Capital #27 Distrib.	6,475,000.00	
413 - 107401 Invest - PLPAH LP		12,950,000.00
410 - 302032 Capital #32 Dist BR		12,950,000.00
410 - 107401 Invest - PLPAH LP	12,950,000.00	
410 - 107204 Invest - PPLP	12,950,000.00	
410 - 302044 Dist #44 PLPAH LP		12,950,000.00

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

SAP contains support for the transfer of stock in 2009 through G/L accounts 302044 (Partnership Distributions) and 130160 (Deposits on Long Term Assets).

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100060152	Company Code	208	Fiscal Year	2009
Doc. Date	08.10.2009	Posting Date	30.09.2009	Period	09
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	RC 0909 23	Overall No.	0100060152208 09		
Doc. Currency	USD				
Doc. Hdr Text	Sept Distributions				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	302044	Dist #44 PLPAH LP		GEN			12.950.000,00	September Distributions
2	50	130160	Deposits On Assets		GEN			12.950.000,00-	September Distributions

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

Audited financial statements for the years ended December 31, 2008 and 2009 show a combined \$36.1 million amount for "Other" investment distributions. Although not explicitly shown, the amount appears to be the combined values of the Kolltan (\$13.0 million) and Novelos (\$23.1 million) transfers (discussed in Exhibit 4E).

	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Partners' Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	<i>(In thousands)</i>						
Balance at December 31, 2008	\$7	\$1,887	\$(999)	\$ 740,455	\$ 10,294	\$(70,405)	\$ 681,239
Deconsolidation of Purdue Pharma Inc.	(1)	(499)	—	—	(573)	—	(1,073)
Deconsolidation of Millsaw Realty Inc.	(1)	—	—	—	(14)	—	(15)
Net income	—	—	—	1,576,714	4,756	—	1,581,470
Other comprehensive income:							
Employee benefit plans, net of tax of \$227	—	—	—	—	—	(9,525)	(9,525)
Currency translation adjustment	—	—	—	—	—	3,005	3,005
Total comprehensive income							1,574,950
Investment distributions:							
Millsaw Realty L.P.	—	—	—	(7,412)	—	—	(7,412)
Infinity Pharmaceuticals Inc.	—	—	—	(11,830)	—	—	(11,830)
Other	—	—	—	(36,090)	—	—	(36,090)
Partners' capital contributions:							
Purdue Pharma L.P.	—	—	—	1,186	—	—	1,186
Partners' capital distributions:							
Pharma Associates L.P.	—	—	—	(20)	—	—	(20)
Norwell Land Company	—	—	—	(742)	—	—	(742)
Purdue Pharma L.P.	—	—	—	(1,609,865)	—	—	(1,609,865)
Balance at December 31, 2009	\$5	\$1,388	\$(999)	\$652,396	\$14,463	\$(76,925)	\$ 590,328

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

SAP contains support for the transfer of stock in 2014 through G/L accounts 103070 (Other Receivables) and 302045 (Partnership Distributions), and the cash payment to PRA L.P. through G/L accounts 100010 (Cash Concentration) and the PRA L.P. Intercompany account (102416)

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100137743	Company Code	208	Fiscal Year	2014
Doc. Date	09.07.2014	Posting Date	30.06.2014	Period	06
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	RK 0614 21				
Doc. Currency	USD				
Doc. Hdr Text	Distributions 06.2014				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
5	50	103070	Marketable Security		GEN			2.050.000,00-	Distributions 06.2014
6	40	302045	Dist #45 PH LP		GEN			2.050.000,00	Distributions 06.2014

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100137427	Company Code	208	Fiscal Year	2014
Doc. Date	06/25/2014	Posting Date	06/22/2014	Period	06
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	CTW416 06162014- Overall No. 0100000446416 14				
Doc. Currency	USD				
Doc. Hdr Text	CWS				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			10,175.00-	CORP PAY
2	50	100010	Cash Concentration		GEN			6,000,000.00-	CORP PAY
3	40	102416	Purdue Holdings LP		GEN			6,010,175.00	

Exhibit 4D: Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

SAP contains support for the distribution of common shares in 2014 through G/L accounts 130160 (Deposits on Long Term Assets) and 302045 (Equity), as well as an additional cash payment of \$547 through account 100010 (Cash Concentration) and 102416 (PRA L.P. Intercompany Account).

Doc.Type : SA (G/L account document) Normal document						
Doc. Number	100144351	Company Code	208	Fiscal Year	2014	
Doc. Date	23.12.2014	Posting Date	31.12.2014	Period	12	
Calculate Tax	<input type="checkbox"/>					
Ref.Doc.	RK 1214 05	Overall No.	0100000529416 14			
Doc. Currency	USD					
Doc. Hdr Text	Rcl Distributions					

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
3	50	130160	Deposits On Assets		GEN			110.880,00-	Distribution of Kolltan Common Stock
4	40	302045	Dist #45 PH LP		GEN			110.880,00	Distribution of Kolltan Common Stock

G/L Account 302045 Distribution #45Purdue Holdings LP
Company Code 208

CoCd	DocumentNo	Postng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
208	100144351	31.12.2014	23.12.2014	12	2014/12	SA		RK 1214 05	302045	GEN	Distribution of Kolltan Common Stock	110.880,00	USD	
208	100144352	31.12.2014	23.12.2014	12	2014/12	SA		RK 1214 06	302045	GEN	Distribution of Kolltan Common Stock	800,00-	USD	
*												110.080,00	USD	

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100144383	Company Code	208	Fiscal Year	2014
Doc. Date	01/05/2015	Posting Date	12/31/2014	Period	12
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	CWS	Overall No.	010000533416 14		
Doc. Currency	USD				
Doc. Hdr Text	CTW416 12222014-12312014				

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			5,801,419.00-	CORP PAY
2	50	100010	Cash Concentration		GEN			1,800,000.00-	CORP PAY
3	50	100010	Cash Concentration		GEN			547.00-	CORP PAY
4	40	102416	Purdue Holdings LP		GEN			7,601,966.00	

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

Purdue entered into a securities purchase agreement with Novelos on February 11, 2009 for 15,384,615 shares of common stock at \$0.65 per share and warrants to acquire up to 9,230,769 shares ("February 2009 Purchase").

EXECUTION COPY

SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT ("Agreement") is made as of this 11th day of February, 2009 by and among Novelos Therapeutics, Inc., a Delaware corporation (the "Company") and Purdue Pharma L.P., a Delaware limited partnership ("Purdue").

Recitals:

A. The Company desires, pursuant to this Agreement, to raise the Investment Amount (as defined below) through the issuance and sale of the following to Purdue (the "Private Placement"): (i) 200 shares (the "Preferred Shares") of a newly created series of the Company's Preferred Stock, designated "Series E Convertible Preferred Stock", par value \$0.00001 per share (the "Preferred Stock"), which Preferred Stock shall have the rights, preferences and privileges set forth in the Certificate of Designations, Preferences and Rights, in the form of Exhibit A annexed hereto and made a part hereof (the "Certificate of Designations"), and each share of Preferred Stock shall have a stated value of \$50,000 and shall initially be convertible into shares of the Company's Common Stock, par value \$0.00001 per share (the "Common Stock"), at a price of \$0.65 per share (the "Conversion Price"), for an aggregate of 15,384,615 shares of Common Stock; and (ii) a warrant to acquire up to 9,230,769 shares of Common Stock, equal to 60% of the number of shares of Common Stock underlying the Preferred Shares on the date of issue, with an exercise price of \$0.65 per share, in the form of Exhibit B annexed hereto and made a part hereof (the "Warrant").

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

Per the securities purchase agreement, the investment totaled \$10 million.

“Requisite Holder” shall mean that Purdue has purchased an aggregate of \$10,000,000 of Preferred Stock pursuant to this Agreement and Purdue and its Associated Companies hold at least one-half of the Preferred Stock issued to Purdue at Closing as of the date of determination (appropriately adjusted for any stock dividend, stock split, reverse stock split, reclassification, stock combination or other recapitalization occurring after the date hereof).

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

PPLP entered into an additional securities purchase agreement with Novelos on August 25, 2009 for 13,636,364 shares of common stock at \$0.66 per share and warrants to acquire 4,772,728 shares ("August 2009 Purchase").

Execution Copy

SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT ("**Agreement**") is made as of this 25th day of August, 2009 by and among Novelos Therapeutics, Inc., a Delaware corporation (the "**Company**") and Purdue Pharma L.P., a Delaware limited partnership ("**Purdue**").

Recitals:

A. The Company desires, pursuant to this Agreement, to raise the Investment Amount (as defined below) through the issuance and sale, in the aggregate, of the following to Purdue (the "**Private Placement**"): (i) 13,636,364 shares (the "**Common Shares**") of Common Stock, par value \$0.00001 per share (the "**Common Stock**"); and (ii) warrants to acquire shares of Common Stock equal to 35% of the aggregate number of shares of Common Stock to be issued and sold to Purdue pursuant to the Closings (as defined below) rounded up to the next even number at each Closing (as defined below), approximately 4,772,728 shares of Common Stock, with an exercise price of \$0.66 per share, each to be in the form of **Exhibit B** annexed hereto and made a part hereof (the "**Warrants**");

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

Per the securities purchase agreement, the investment totaled \$9 million.

“Investment Amount” means an amount equal to \$9,000,000.24.

“License Agreements” has the meaning set forth in Section 5.14(b).

“Losses” has the meaning set forth in Section 9.2.

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

An internal analysis, which appears dated August 25, 2009, calculates the fair value of the August 2009 purchase at approximately \$13.1 million. The \$13.1 million fair market value for August 2009 plus \$10 million paid for the February 2009 purchase appears to support the \$23.1 million transfer price.

Purdue Pharma L.P.

Novelos Transactions - Summary of Fair Values of Assets Received

August 25, 2009

	# of Shares/ Warrants	Unit value	Calculated Fair Value	
Fair value of 13,636,364 shares of common stock	13,636,364	\$0.79	\$10,772,728	Distributed on 8/25/09
Fair value of warrants to purchase 4,772,728 common shares	4,772,728	\$0.50	2,367,370	Distributed on 8/25/09
Fair value of right to exclusive negotiation period			0	
			13,140,097	
Less amount paid			9,000,000	
Gain on transaction			\$4,140,097	

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

Audited financial statements for the years ended December 31, 2008 and 2009 show a combined \$36.1 million amount for "Other" investment distributions. Although not explicitly shown, the amount appears to be the combined values of the Kolltan transfers (\$13.0 million, discussed in Exhibit 4D) and Novelos transfers (\$23.1 million) .

	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Partners' Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	<i>(In thousands)</i>						
Balance at December 31, 2008	\$7	\$1,887	\$(999)	\$ 740,455	\$ 10,294	\$(70,405)	\$ 681,239
Deconsolidation of Purdue Pharma Inc.	(1)	(499)	—	—	(573)	—	(1,073)
Deconsolidation of Millsaw Realty Inc.	(1)	—	—	—	(14)	—	(15)
Net income	—	—	—	1,576,714	4,756	—	1,581,470
Other comprehensive income:							
Employee benefit plans, net of tax of \$227	—	—	—	—	—	(9,525)	(9,525)
Currency translation adjustment	—	—	—	—	—	3,005	3,005
Total comprehensive income							1,574,950
Investment distributions:							
Millsaw Realty L.P.	—	—	—	(7,412)	—	—	(7,412)
Infinity Pharmaceuticals Inc.	—	—	—	(11,830)	—	—	(11,830)
Other	—	—	—	(36,090)	—	—	(36,090)
Partners' capital contributions:							
Purdue Pharma L.P.	—	—	—	1,186	—	—	1,186
Partners' capital distributions:							
Pharma Associates L.P.	—	—	—	(20)	—	—	(20)
Norwell Land Company	—	—	—	(742)	—	—	(742)
Purdue Pharma L.P.	—	—	—	(1,609,865)	—	—	(1,609,865)
Balance at December 31, 2009	\$5	\$1,388	\$(999)	\$652,396	\$14,463	\$(76,925)	\$ 590,328

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

The non-cash transfer was recognized as follows in PPLP's (SAP company code 208) accounting records. Below is the accounting of the \$10 million February 2009 distribution.

Company	Account Number	Account Description	DR	CR
208	302044	Dist #44 PLPAH LP	\$ 10,000,000	
208	107955	Investment Novelos		\$ (10,000,000)
401	302032	Capital #32 Dist BR	\$ 39,012,199 ¹	
401	107204	Invest - PPLP		\$ (39,012,199)
413	107401	Invest. PLP Asc. Hold		\$ (39,012,199)
413	302026	Capital #26 Distribution	\$ 19,506,100	
413	302027	Capital #27 Distribution	19,506,100	

208: Purdue Pharma L.P.

401: PLP Assoc Holdings L.P.

413: BR Holdings Assoc. LP

¹The \$10 million Novelos distribution was recorded in SAP along with the 2009 \$30 million original purchase of Infinity stock (discussed in Exhibit 4B). Within SAP, the selected \$10 million Novelos distribution is netted by miscellaneous NJ Refunds/Interest (\$10,000,000 - \$987,801.22 = \$9,012,198.78).

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

SAP contains support for the \$10 million February 2009 transfer of equity through PPLP's G/L accounts 302044 (equity) and 107955 (investment in affiliated companies).

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100050035	Company Code	208	Fiscal Year	2009
Doc. Date	04.03.2009	Posting Date	28.02.2009	Period	02
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	RC 0209 03	Overall No.	0100050035208 09		
Doc. Currency	USD				
Doc. Hdr Text	Distributions				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
5	40	302044	Dist #44 PLPAH LP		GEN			10.000.000,00	Novelos Distribution
6	50	107955	Investment Novelos		GEN			10.000.000,00-	Novelos Distribution

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

SAP contains support for the \$10 million February 2009 transfer of equity through BR Holdings Assoc. LP (an indirect parent of PPLP – SAP company code 413).

G/L account document						
Overall No. 0100050035208 09 Doc. Currency USD						

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itr	PK Account	Account short text		Assignment	Tx		Amount Text

208	100050035	2009	SA	04.03.2009	28.02.2009	RC 0209 03	USD
1	40 302044	Dist #44 PLPAH LP		20090304	30.000.000,00		Infinity Distribution
2	50 107950	Investment Infinity		20090304	15.000.000,00-		Infinity Distribution
3	40 302043	Dist #43 PLPAH Inc		20090304	74.289,57		Infinity Distribution
4	40 302042	Dist #42 PP Inc		20090304	74.618,55		Infinity Distribution
5	40 302044	Dist #44 PLPAH LP		20090304	10.000.000,00		Novelos Distribution
6	50 107955	Investment Novelos		20090304	10.000.000,00 ¹		Novelos Distribution
7	40 302043	Dist #43 PLPAH Inc		20090304	24.763,19		Novelos Distribution
8	40 302042	Dist #42 PP Inc		20090304	24.872,85		Novelos Distribution
9	40 302040	Dist IRC 1446		20090304	961.731,70		NJ Refund
10	50 302044	Dist #44 PLPAH LP		20090304	961.731,70-		NJ Refund
11	50 302043	Dist #43 PLPAH Inc		20090304	2.381,55-		NJ Refund
12	50 302042	Dist #42 PP Inc		20090304	2.392,10-		NJ Refund
13	40 302040	Dist IRC 1446		20090304	25.268,30		NJ Refund - Interest
14	50 302044	Dist #44 PLPAH LP		20090304	25.268,30-		NJ Refund - Interest
15	50 302043	Dist #43 PLPAH Inc		20090304	62,57-		NJ Refund - Interest
16	50 302042	Dist #42 PP Inc		20090304	62,85-		NJ Refund - Interest
17	50 302044	Dist #44 PLPAH LP		20090304	801,22-		NC Refund
18	50 302043	Dist #43 PLPAH Inc		20090304	1,98-		NC Refund
19	50 302042	Dist #42 PP Inc		20090304	1,99-		NC Refund
20	50 102301	Purdue Pharma Inc.		20090304	97.034,46-		
21	50 102313	Purdue Pharm Prod LP		20090304	15.000.000,00-		
22	50 102402	PLP Assoc Holdings		20090304	96.606,66-		
23	40 102412	IRC 1446 W/H Partner		20090304	801,22		

401	100000388	2009	SA	04.03.2009	28.02.2009	RC 0209 03	USD
1	50 107204	Invest - PPLP		20090304	39.012.198,78-		February Distributions
2	40 302032	Capital #32 Dist BR		20090304	39.012.198,78		February Distributions

413	100000162	2009	SA	04.03.2009	28.02.2009	RC 0209 03	USD
1	40 302026	Capital #26 Distrib.		20090304	19.506.099,39		February Distributions
2	40 302027	Capital #27 Distrib.		20090304	19.506.099,39		February Distributions
3	50 107401	Invest. PLP Asc.Hold		20090304	39.012.198,78-		February Distributions

¹The \$10 million Novelos distribution was recorded in SAP along with the 2009 \$30 million original purchase of Infinity stock (discussed in Exhibit 4B). Within SAP, the selected \$10 million Novelos distribution is netted by miscellaneous NJ Refunds/Interest (\$10,000,000 - \$987,801.22 = \$9,012,198.78).

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

The non-cash transfer was recognized as follows in PPLP's (SAP company code 208) accounting records. Below is the accounting of its book value of the \$9 million August 2009 distribution.

Company	Account Number	Account Description	DR	CR
208	302044	Dist #44 PLPAH LP	\$ 5,500,000	
208	107955	Investment Novelos		\$ (5,500,000)
401	302032	Capital #32 Dist BR	\$ 5,500,000	
401	107204	Invest - PPLP		\$ (5,500,000) ¹
413	107401	Invest. PLP Asc. Hold		\$ (5,500,000)
413	302026	#26 Distribution Beacon Company	\$ 2,750,000	
413	302027	#27 Distribution Rosebay	2,750,000	
208	302044	Dist #44 PLPAH LP	\$ 3,500,000	
208	107955	Investment Novelos		\$ (3,500,000)
401	302032	Capital #32 Dist BR	\$ 3,500,000	
401	107204	Invest - PPLP		\$ (3,500,000)
413	107401	Invest. PLP Asc. Hold		\$ (3,500,000) ¹
413	302026	#26 Distribution Beacon Company	\$ 1,750,000	
413	302027	#27 Distribution Rosebay	1,750,000	

208: Purdue Pharma L.P.

401: PLP Assoc Holdings L.P.

413: BR Holdings Assoc. LP

¹\$5,500,000 + \$3,500,000 = \$9,000,000.

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

SAP contains support for the \$9 million transfer of equity through PPLP's G/L accounts 302044 (equity) and 107955 (investment in affiliated companies).

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100062757	Company Code	208	Fiscal Year	2009
Doc. Date	07.12.2009	Posting Date	30.11.2009	Period	11
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	RC 1109 22	Overall No.	0100062757208 09		
Doc. Currency	USD				
Doc. Hdr Text	Nov Distr - Novelos				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	302044	Dist #44 PLPAH LP		GEN			5.500.000,44	November Distribution- Novelos
2	50	107955	Investment Novelos		GEN			5.500.000,44 ¹	November Distribution- Novelos

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100058807	Company Code	208	Fiscal Year	2009
Doc. Date	09.09.2009	Posting Date	31.08.2009	Period	08
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	RC 0809 10	Overall No.	0100058807208 09		
Doc. Currency	USD				
Doc. Hdr Text	Aug Distr - Novelos				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	302044	Dist #44 PLPAH LP		GEN			3.499.999,80 ¹	August Distribution- Novelos
2	50	107955	Investment Novelos		GEN			3.499.999,80 ¹	August Distribution- Novelos

¹\$5,500,000.44 + \$3,499,999.80 = \$9,000,000.24.

Exhibit 4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

SAP contains support for the \$9 million transfer of equity through PPLP's G/L accounts 302044 (equity) and 107955 (investment in affiliated companies).

G/L account document						
Overall No.		0100058807208 09		Doc. Currency USD		

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	FK Account	Account short text		Assignment	Tx	Amount Text	

208	100062757	2009	SA	07.12.2009	30.11.2009	RC 1109 22	USD
1 40	302044	Dist #44 PLPAH LP		20091207		5.500.000,44	November Distribution- Novelos
2 50	107955	Investment Novelos		20091207		5.500.000,44-	November Distribution- Novelos

401	100000537	2009	SA	07.12.2009	30.11.2009	RC 1109 22	USD
2 50	107204	Invest - PPLP		20091207		5.500.000,44-	November Distribution- Novelos
3 40	302032	Capital #32 Dist BR		20091207		5.500.000,44	November Distribution- Novelos

413	100000233	2009	SA	07.12.2009	30.11.2009	RC 1109 22	USD
1 40	302026	Capital #26 Distrib.		20091207		2.750.000,22	November Distribution- Novelos
2 40	302027	Capital #27 Distrib.		20091207		2.750.000,22	November Distribution- Novelos
3 50	107401	Invest. PLP Asc.Hold		20091207		5.500.000,44 ¹	November Distribution- Novelos

G/L account document						
Overall No.		0100062757208 09		Doc. Currency USD		

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	FK Account	Account short text		Assignment	Tx	Amount Text	

208	100058807	2009	SA	09.09.2009	31.08.2009	RC 0809 10	USD
1 40	302044	Dist #44 PLPAH LP		20090909		3.499.999,80	August Distribution- Novelos
2 50	107955	Investment Novelos		20090909		3.499.999,80-	August Distribution- Novelos
3 40	302043	Dist #43 PLPAH Inc		20090909		8.667,12	August Distribution- Novelos
4 40	302042	Dist #42 PP Inc		20090909		8.705,50	August Distribution- Novelos
5 50	102301	Purdue Pharma Inc.		20090909		8.705,50-	
6 50	102402	PLP Assoc Holdings		20090909		8.667,12-	

401	100000493	2009	SA	09.09.2009	31.08.2009	RC 0809 10	USD
1 50	107204	Invest - PPLP		20090909		3.499.999,80-	August Distribution- Novelos
2 40	302032	Capital #32 Dist BR		20090909		3.499.999,80	August Distribution- Novelos

413	100000210	2009	SA	09.09.2009	31.08.2009	RC 0809 10	USD
1 40	302026	Capital #26 Distrib.		20090909		1.749.999,90	August Distribution- Novelos
2 40	302027	Capital #27 Distrib.		20090909		1.749.999,90	August Distribution- Novelos
3 50	107401	Invest. PLP Asc.Hold		20090909		3.499.999,80 ¹	August Distribution- Novelos

1) \$5,500,000.44 + \$3,499,999.80 = \$9,000,000.24

Exhibit 4F: Transfer from Purdue of its equity interest in Lucien Holdings S.ar.l. to PRA L.P. in 2010 at a valuation of negative \$0.5 million

On April 30, 2010, PPLP and PRA L.P. entered into an assignment and assumption agreement over the 100% interest in Lucien.

ASSIGNMENT AND ASSUMPTION AGREEMENT

This Assignment and Assumption Agreement (the "Agreement") effective April 30, 2010 (the "Assignment Date") by and between Purdue Pharma L.P., a Delaware limited partnership ("Assignor"), and Purdue Holdings L.P., a Delaware limited partnership ("Assignee");

W I T N E S S E T H :

WHEREAS, Assignor has distributed 100% of Assignor's interest in Lucien Holdings S.ar.l. ("Lucien"), a Luxembourg company (the "Lucien Interest") held by the Assignor to Assignee; and

WHEREAS, Assignor has distributed 100% of Assignor's interest in New Suffolk Holdings LLP, a Delaware limited liability partnership (the "New Suffolk Interest") held by the Assignor to Assignee; and

WHEREAS, Assignor has distributed 100% of Assignor's interest in RSJ Company L.P., a Delaware limited partnership (the "RSJ Interest") held by the Assignor to Assignee; and

WHEREAS, Assignor has distributed 100% of Assignor's interest in the debt obligations owed to Assignor by Lucien and Lucien's wholly-owned subsidiaries (the "Lucien Debt Obligations") held by the Assignor to Assignee; and

Exhibit 4F: Transfer from Purdue of its equity interest in Lucien Holdings S.ar.l. to PRA L.P. in 2010 at a valuation of negative \$0.5 million

On April 1, 2010, a meeting of the Board of Directors of PPI was held that authorized the transfer of Lucien to PPLP.

PURDUE PHARMA INC.

Minutes of a Meeting of the Board of Directors

April 1, 2010

RESOLVED, that, effective April 30, 2010, the Partnership be and it hereby is authorized and directed to distribute 100% of the Partnership's interests in the following companies to PHLP:

- Lucien Holdings S.ar.l., a Luxembourg company ("Lucien");
- New Suffolk Holdings LLP, a Delaware limited liability partnership ("New Suffolk"); and
- RSJ Company L.P., a Delaware limited partnership ("RSJ")

Exhibit 4F: Transfer from Purdue of its equity interest in Lucien Holdings S.ar.l. to PRA L.P. in 2010 at a valuation of negative \$0.5 million

Per the 2010 audited financial statements, Purdue transferred the equity interest at book value of negative \$0.5 million.

The Companies' Combined Statement of Equity

	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Partners' Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	<i>(In thousands)</i>						
Net income	—	—	—	1,603,503	1,894	—	1,605,397
Other comprehensive income:							
Employee benefit plans, net of tax benefit of \$263	—	—	—	—	—	(5,147)	(5,147)
Lucien currency translation adjustment elimination	—	—	—	—	—	(4,464)	(4,464)
Total comprehensive income							1,595,786
Investment distributions:							
New Suffolk Holdings LLP	—	—	—	(32,761)			(32,761)
Lucien Holdings S.ar.l.	—	—	—	542			542
Partners' capital distributions:							
Pharma Associates L.P.	—	—	—	(20)	—	—	(20)
Norwell Land Company	—	—	—	(728)	—	—	(728)
Purdue Pharma L.P.	—	—	—	(1,626,174)	—	—	(1,626,174)
Balance at December 31, 2010	\$5	\$1,388	\$(999)	\$596,758	\$16,357	\$(86,536)	\$ 526,973

Lucien is a limited partner in eight start-up companies each with operations in France, Belgium, Italy, Netherlands, Norway, Finland, Spain and Portugal (the "Start-ups"). During the years ended December 31, 2010 and 2009, PPLP invested \$8.3 million and \$86.9 million, respectively, in the Start-ups. The Start-ups develop, manufacture and sell pharmaceutical products, which are marketed primarily to the medical and health care industries in their respective countries. The Start-up investments are accounted for in accordance with the equity method of accounting. During the years ended December 31, 2010 and 2009, PPLP recognized equity losses of \$8.3 million and \$86.9 million, respectively, as a result of Lucien's investments in the Start-ups. On April 1, 2010, the partners of PPLP authorized the distribution of PPLP's ownership in Lucien to its limited partner with an effective date of April 30, 2010.

Exhibit 4F: Transfer from Purdue of its equity interest in Lucien Holdings S.ar.l. to PRA L.P. in 2010 at a valuation of negative \$0.5 million

Per an internal calculation file, Purdue transferred the Lucien equity interest on May 1, 2010 at Book Value of negative \$0.5 million.

Purdue Combined
Lucien Holdings S.ar.l.
4/30/2010

	1/1/2008	2008 Activity	12/31/2008	2009 Activity	12/31/2009	2010 Activity (Note 1)	4/30/2010	Distribution up to PHLP on 5/1/2010	Balances after distribution up
Cash and cash equivalents	\$ 606	\$ 1,955	\$ 2,561	\$ 1,596	\$ 4,157	-	\$ 4,157	\$ (4,157)	\$ -
Accrued expenses and other liabilities	(190)	(937)	(1,127)	892	(235)	-	(235)	235	-
Current debt - Associated companies	(41,770)	1,792	(39,978)	39,978	-	-	-	-	-
Partners' capital	41,216	(1,213)	40,003	(39,461)	542	-	542	(542)	-
Accumulated other comprehensive loss	138	(1,597)	(1,459)	(3,005)	(4,464)	-	(4,464)	4,464	-
	-	-	-	-	-	-	-	-	-
Partners' capital - Beginning of period			\$ 41,216		\$ 40,003		542		
Capital contributions			(67,508)		(122,507)		(8,284)		
P&L			66,295		83,046		8,284		
Partners' capital - End of period			<u>\$ 40,003</u>		<u>\$ 542</u>		<u>\$ 542</u>		
P&L Activity is write off of investment									
Nontag Sarl						3/4/2010	3,471		
Filti Sarl						1/23/2010	3,267		
Songol Sarl						4/2/2010	3,466		
Interest Received							(1,920)		
Note 1 - activity in Q1 2010 was insignificant so no journal entries were recorded.							<u>8,284</u>		

Exhibit 4F: Transfer from Purdue of its equity interest in Lucien Holdings S.ar.l. to PRA L.P. in 2010 at a valuation of negative \$0.5 million

The non-cash transfer was recognized as follows in PPLP's (SAP company code 208) accounting records.

Company	Account Number	Account Description	DR	CR
208	302045	Dist #45 PH LP	\$ 3,922,000	
208	107233	Invest - Lucien		\$ (3,922,000)
416	107233	Invest - Lucien	\$ 3,922,000	
416	107204	Invest - PPLP		\$ (3,922,000)
208	107233	Invest - Lucien	\$ 4,463,769	
208	700130	Partnership Income		\$ (4,463,769)
291	700130	Partnership Income	\$ 4,463,769	
291	107233	Invest - Lucien		\$ (4,463,769)

208: Purdue Pharma L.P.

416: Pharmaceutical Research Associates L.P.

291: Rhodes/PPLP Eliminations

Note: \$3.9 million - \$ 4.4 million = negative \$0.5 million. Per Purdue, Equity contribution is negative where cash investments by PPLP are less than the equity share of its losses

Exhibit 4F: Transfer from Purdue of its equity interest in Lucien Holdings S.ar.l. to PRA L.P. in 2010 at a valuation of negative \$0.5 million

SAP contains support for the negative \$0.5 million transfer of equity through PPLP's G/L accounts 302045 (equity), 107233 (investments in associated companies) and 700130 (Partnership Income).

Doc.Type : ZH (G/L acct doc Accrual) Normal document

Doc. Number100070795Company Code208Fiscal Year2010

Doc. Date06/29/2010Posting Date05/31/2010Period05

Calculate Tax☐

Ref.Doc.CT 0502 04Overall No.0100070795208 10

Doc. CurrencyUSD

Doc. Hdr TextCT 0502 04

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	302045	Dist #45 PH LP		GEN			3,922,000.00	To distribute PPLP's share in Lucien to PHLP
2	50	107233	Invest - Lucien		GEN			3,922,000.00-	To distribute PPLP's share in Lucien to PHLP

Doc.Type : ZH (G/L acct doc Accrual) Normal document

Doc. Number100070794Company Code208Fiscal Year2010

Doc. Date06/29/2010Posting Date04/30/2010Period04

Calculate Tax☐

Ref.Doc.CT 0410 04Overall No.0100070794208 10

Doc. CurrencyUSD

Doc. Hdr TextCT 0410 04

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	700130	Partnership Income	9000208	GEN			66,295,446.53	To record Lucien's 2008 equity loss.
2	50	107233	Invest - Lucien		GEN			66,295,446.53-	To record Lucien's 2008 equity loss.
3	40	300040	Capital #40 IRC 1446		GEN			41,215,746.27	To correct PPLP's investment in Lucien
4	50	107233	Invest - Lucien		GEN			41,215,746.27-	To correct PPLP's investment in Lucien
5	40	107233	Invest - Lucien		GEN			4,463,769.27	PPLP's share of 233's Foreign Currency
6	50	700130	Partnership Income	9000208	GEN			4,463,769.27-	PPLP's share of 233's Foreign Currency
7	40	700130	Partnership Income	9000208	GEN			8,284,675.18	PPLP's share of Luciens 4/30/2010 equity
8	50	107233	Invest - Lucien		GEN			8,284,675.18-	PPLP's share of Luciens 4/30/2010 equity

Note: \$3.9 million - \$ 4.4 million = negative \$0.5 million. Per Purdue, Equity contribution is negative where cash investments by PPLP are less than the equity share of its losses

Exhibit 4G: Transfer from Purdue of its equity interest in New Suffolk Holdings LLP to PRA L.P. in 2010 at a valuation of \$32.8 million

On April 30, 2010, PPLP and PRA L.P. entered into an assignment and assumption agreement over the 100% interest in NSH.

ASSIGNMENT AND ASSUMPTION AGREEMENT

This Assignment and Assumption Agreement (the "Agreement") effective April 30, 2010 (the "Assignment Date") by and between Purdue Pharma L.P., a Delaware limited partnership ("Assignor"), and Purdue Holdings L.P., a Delaware limited partnership ("Assignee");

W I T N E S S E T H :

WHEREAS, Assignor has distributed 100% of Assignor's interest in Lucien Holdings S.ar.l. ("Lucien"), a Luxembourg company (the "Lucien Interest") held by the Assignor to Assignee; and

WHEREAS, Assignor has distributed 100% of Assignor's interest in New Suffolk Holdings LLP, a Delaware limited liability partnership (the "New Suffolk Interest") held by the Assignor to Assignee; and

WHEREAS, Assignor has distributed 100% of Assignor's interest in RSJ Company L.P., a Delaware limited partnership (the "RSJ Interest") held by the Assignor to Assignee; and

WHEREAS, Assignor has distributed 100% of Assignor's interest in the debt obligations owed to Assignor by Lucien and Lucien's wholly-owned subsidiaries (the "Lucien Debt Obligations") held by the Assignor to Assignee; and

Exhibit 4G: Transfer from Purdue of its equity interest in New Suffolk Holdings LLP to PRA L.P. in 2010 at a valuation of \$32.8 million

Per the 2010 audited financial statements, Purdue transferred the equity interest of NSH at a \$32.8 million book value.

	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Partners' Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	<i>(In thousands)</i>						
Net income	—	—	—	1,603,503	1,894	—	1,605,397
Other comprehensive income:							
Employee benefit plans, net of tax benefit of \$263	—	—	—	—	—	(5,147)	(5,147)
Lucien currency translation adjustment elimination	—	—	—	—	—	(4,464)	(4,464)
Total comprehensive income							1,595,786
Investment distributions:							
New Suffolk Holdings LLP	—	—	—	(32,761)			(32,761)
Lucien Holdings S.ar.l.	—	—	—	542			542
Partners' capital distributions:							
Pharma Associates L.P.	—	—	—	(20)	—	—	(20)
Norwell Land Company	—	—	—	(728)	—	—	(728)
Purdue Pharma L.P.	—	—	—	(1,626,174)	—	—	(1,626,174)
Balance at December 31, 2010	\$5	\$1,388	\$(999)	\$596,758	\$16,357	\$(86,536)	\$ 526,973

Exhibit 4G: Transfer from Purdue of its equity interest in New Suffolk Holdings LLP to PRA L.P. in 2010 at a valuation of \$32.8 million

Per an internal calculation file, Purdue transferred the stake in NSH on May 1, 2010 at a book value of \$32.8 million.

Purdue Combined
New Suffolk Holdings LLP
4/30/2010

	1/1/2008	2008 Activity	12/31/2008	2009 Activity	12/31/2009	2010 Activity	4/30/2010	Distribution up to PHLP on 5/1/2010	Balances after distribution up
Cash and cash equivalents	\$ -	\$ 1	\$ 1	\$ -	\$ 1	-	1	(1)	-
Investment in Germany	-	12,995	12,995	16,706	29,701	3,157	32,858	(32,858)	-
Due from (to) associated companies	-	-	-	(80)	(80)	(18)	(98)	98	-
Partners' capital	-	(12,996)	(12,996)	(16,626)	(29,622)	(3,139)	(32,761)	32,761	-
	-	-	-	-	-	-	-	-	-
Partners' capital - Beginning of period			\$ -		\$ (12,996)		(29,622)		
Capital contributions			(12,704)		(12,781)		-		
P&L			(292)		(3,845)		(3,139)		
Partners' capital - End of period			<u>\$ (12,996)</u>		<u>\$ (29,622)</u>		<u>(32,761)</u>		

Exhibit 4G: Transfer from Purdue of its equity interest in New Suffolk Holdings LLP to PRA L.P. in 2010 at a valuation of \$32.8 million

The non-cash transfer was recognized as follows in PPLP's (SAP company code 208) accounting records.

Company	Account Number	Account Description	DR	CR
208	302045	Dist #45 PH LP	\$ 32,761,081	
208	107232	Invest New Suffolk Holdings L.P.		\$ (32,761,081)
416	107232	Invest New Suffolk Holdings L.P.	\$ 32,761,081	
416	107204	Invest - PPLP		\$ (32,761,081)

208: Purdue Pharma L.P.

416: Pharmaceutical Research Associates L.P.

Exhibit 4G: Transfer from Purdue of its equity interest in New Suffolk Holdings LLP to PRA L.P. in 2010 at a valuation of \$32.8 million

SAP contains support for the transfer of equity through PPLP's G/L accounts 107232 (investments in affiliated companies) and 302045 (equity).

Document Overview - Display

Exhibit 4G: Transfer from Purdue of its equity interest in New Suffolk Holdings LLP to PRA L.P. in 2010 at a valuation of \$32.8 million

SAP contains support for the \$32.8 million transfer of equity through PPLP's G/L accounts 302045 (equity) and 107232 (investment in affiliated companies).

G/L account document								
Overall No.		0100070853208 10		Doc. Currency USD				
CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy	
Itm	PK Account	Account short text		Assignment		Tx	Amount	Text
208	100070853	2010	SA	30.06.2010	31.05.2010	ASM 0510 05	USD	
1	50 107232	Invest - New Suffolk		20100630			32.761.080,84-	to record NSH distribution up from 208 to Purdue H
2	40 302045	Dist #45 PH LP		20100630			32.761.080,84	to record NSH distribution up from 208 to Purdue H
406 ¹	100000042	2010	SA	30.06.2010	31.05.2010	ASM 0510 05	USD	
1	50 302045	Dist #45 PH LP		20100630			32.761.080,84-	to record NSH distribution up from 208 to Purdue H
2	40 107204	Invest - PPLP		20100630			32.761.080,84	to record NSH distribution up from 208 to Purdue H
416	100000014	2010	SA	30.06.2010	31.05.2010	ASM 0510 05	USD	
1	40 107232	Invest - New Suffolk		20100630			32.761.080,84	to record NSH distribution up from 208 to Purdue H
2	50 107204	Invest - PPLP		20100630			32.761.080,84-	to record NSH distribution up from 208 to Purdue H

¹SAP company code 406 corresponds to PPLP & PHLP Eliminations.

Exhibit 4H: Transfer from Purdue of its rights to royalty payments from foreign IACs on non-ADF OxyContin to PRA L.P. in 2017

Per discussions with Purdue, PPLP no longer wanted to sell or receive income for non-ADF products. As a result, the royalties earned on non-ADF OxyContin sales were transferred for no consideration. AlixPartners has reviewed numerous assignment & assumption agreements dated January 1, 2017 (by country/region); however, no consideration is discussed in the agreements.

ASSIGNMENT AND ASSUMPTION AGREEMENT (OxyContin® Preparations - Iceland)

This Assignment and Assumption Agreement (the “Agreement”) effective January 1, 2017 (the “Assignment Date”) is by and between Purdue Pharma L.P., a Delaware limited partnership (“Assignor”), and Purdue Holdings L.P. a Delaware limited partnership (“Assignee”);

W I T N E S S E T H :

WHEREAS, Assignor and Mundipharma D.C. BV entered into that certain Manufacturer’s Licence Agreement for OxyContin® Preparation for the territory of Iceland, dated January 1, 2016 (the “Licence Agreement”);

WHEREAS, pursuant to Section 2.9.1 of the Licence Agreement, Assignor may assign or transfer its rights thereunder;

WHEREAS, in connection with the foregoing right, Assignor desires to assign and Assignee desires to assume the Licence Agreement upon the terms and conditions set forth herein.

Exhibit 4H: Transfer from Purdue of its rights to royalty payments from foreign IACs on non-ADF OxyContin to PRA L.P. in 2017

The table below summarizes the countries and regions mentioned in the various assignment & assumption agreements dated January 1, 2017.

Regions Covered in Agreements			
Arab States	France	Lebanon	South Africa
Austria	Germany	Netherlands	Spain
Belgium	Hong Kong	New Zealand	Sweden
Cen. & East Europe	Iceland	Norway	Switzerland
China	Ireland	Philippines	United Kingdom
Cyprus	Italy	Poland	
Denmark	Jordan	Saudi Arabia	
Finland	Kuwait	Singapore	